Mashudu Madzivhandila

Johannesburg, GT, South Africa

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

Humoral, T cell and immune gene expression responses to SARS-CoV-2 vaccination in a small group of children with previous MIS-C.

Humoral, T cell and immune gene expression responses to SARS-CoV-2 vaccination in a small group of children with previous MIS-C.

Journal: Vaccine

Published: August 18, 2024

Safety and immunogenicity of booster vaccination and fractional dosing with Ad26.COV2.S or BNT162b2 in Ad26.COV2.S-vaccinated participants.

Safety and immunogenicity of booster vaccination and fractional dosing with Ad26.COV2.S or BNT162b2 in Ad26.COV2.S-vaccinated participants.

Journal: PLOS global public health

Published: December 04, 2023

Safety and immunogenicity of booster vaccination and fractional dosing with Ad26.COV2.S or BNT162b2 in Ad26.COV2.S-vaccinated participants.

Safety and immunogenicity of booster vaccination and fractional dosing with Ad26.COV2.S or BNT162b2 in Ad26.COV2.S-vaccinated participants.

Journal: medRxiv : the preprint server for health sciences

Published: December 04, 2023

Comparing the immune abnormalities in MIS-C to healthy children and those with inflammatory disease reveals distinct inflammatory cytokine production and a monofunctional T cell response.

Comparing the immune abnormalities in MIS-C to healthy children and those with inflammatory disease reveals distinct inflammatory cytokine production and a monofunctional T cell response.

Journal: Clinical immunology (Orlando, Fla.)

Published: September 04, 2023

Shared N417-Dependent Epitope on the SARS-CoV-2 Omicron, Beta, and Delta Plus Variants.

Shared N417-Dependent Epitope on the SARS-CoV-2 Omicron, Beta, and Delta Plus Variants.

Journal: Journal of virology

Published: July 22, 2022

Cross-Reactive Neutralizing Antibody Responses Elicited by SARS-CoV-2 501Y.V2 (B.1.351).

Cross-Reactive Neutralizing Antibody Responses Elicited by SARS-CoV-2 501Y.V2 (B.1.351).

Journal: The New England journal of medicine

Published: April 07, 2021

SARS-CoV-2 501Y.V2 (B.1.351) elicits cross-reactive neutralizing antibodies.

SARS-CoV-2 501Y.V2 (B.1.351) elicits cross-reactive neutralizing antibodies.

Journal: bioRxiv : the preprint server for biology

Published: March 10, 2021

SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma.

SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma.

Journal: bioRxiv : the preprint server for biology

Published: January 27, 2021

SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma.

SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma.

Journal: Nature medicine

Published: January 21, 2021

Case report: mechanisms of HIV elite control in two African women.

Case report: mechanisms of HIV elite control in two African women.

Journal: BMC infectious diseases

Published: July 09, 2017

HIV and risk of cardiovascular disease in sub-Saharan Africa: Rationale and design of the Ndlovu Cohort Study.

HIV and risk of cardiovascular disease in sub-Saharan Africa: Rationale and design of the Ndlovu Cohort Study.

Journal: European journal of preventive cardiology

Published: April 06, 2017

Distribution of pilus islands of group B streptococcus associated with maternal colonization and invasive disease in South Africa.

Distribution of pilus islands of group B streptococcus associated with maternal colonization and invasive disease in South Africa.

Journal: Journal of medical microbiology

Published: October 16, 2012

Showing 1-12 of 12

Last Updated: 09/26/2026